Michèle Janine Hoffmann (Michéle J Hoffmann, Michèle Hoffmann, Michèle J Hoffmann)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 24

Top Topics

Squamous Cell Carcinoma

Dna Methylation

Histone Deacetylase

Top Venues

Journal of cellular and molecular medicine

Scientific reports

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Sarah Meneceur, Caroline E De Vos, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of cellular and molecular medicine 28 (9) (2024)
Aaron Burmeister, Alexa Stephan, Leandro A Alves Avelar, Melanie R Müller, Andrea Seiwert, Stefan Höfmann, Fabian Fischer, Hector Torres-Gomez, Michèle Janine Hoffmann, Guenter Niegisch, Felix Bremmer, Patrick Petzsch, Karl Köhrer, Peter Albers, Thomas Kurz, Margaretha A Skowron, Daniel Nettersheim
Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies. Molecular cancer therapeutics 21 (11) (2022)
Ananda Ayyappan Jaguva Vasudevan, Michèle Janine Hoffmann, Gereon Poschmann, Patrick Petzsch, Constanze Wiek, Kai Stühler, Karl Köhrer, Wolfgang A Schulz, Guenter Niegisch
Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression. Scientific data 9 (1) (2022)
Pauline Ott, Marcos Jesus Araúzo-Bravo, Michèle Janine Hoffmann, Cedric Poyet, Marcelo L Bendhack, Simeon Santourlidis, Lars Erichsen
Differential DNA Methylation of THOR and hTAPAS in the Regulation of hTERT and the Diagnosis of Cancer. Cancers 14 (18) (2022)
Michèle Janine Hoffmann, Wolfgang A Schulz
Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma. Cancers 13 (23) (2021)
Michèle Janine Hoffmann, Sarah Meneceur, Katrin Hommel, Wolfgang A Schulz, Guenter Niegisch
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. Genes 12 (2) (2021)
Sophia Thy, Alexandra Hommel, Sarah Meneceur, Anna L Bartkowiak, Wolfgang A Schulz, Guenter Niegisch, Michèle Janine Hoffmann
Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment. Cancers 13 (6) (2021)
Lena Berning, David Schlütermann, Annabelle Friedrich, Niklas Berleth, Yadong Sun, Wenxian Wu, María José Mendiburo, Jana Deitersen, Hannah U C Brass, Margaretha A Skowron, Michèle Janine Hoffmann, Guenter Niegisch, Jörg Pietruszka, Björn Stork
Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment. Molecules (Basel, Switzerland) 26 (5) (2021)
Tibor Szarvas, Michèle Janine Hoffmann, Csilla Olah, Eszter Szekely, András Kiss, Jochen Hess, Stephan Tschirdewahn, Boris Hadaschik, Vera Grotheer, Peter Nyirady, Anita Csizmarik, Melinda Varadi, Henning Reis
MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics (Basel, Switzerland) 11 (1) (2020)
Csilla Olah, Stephan Tschirdewahn, Michèle Janine Hoffmann, Ulrich Krafft, Boris Hadaschik, Peter Nyirady, Attila Szendröi, Orsolya Módos, Anita Csizmarik, Ilona Kovalszky, Henning Reis, Tibor Szarvas
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. Diagnostics (Basel, Switzerland) 10 (11) (2020)
Patcharawalai Whongsiri, Wolfgang Goering, Tobias Lautwein, Christiane Hader, Guenter Niegisch, Karl Köhrer, Michèle Janine Hoffmann, Wolfgang A Schulz
Many Different LINE-1 Retroelements Are Activated in Bladder Cancer. International journal of molecular sciences 21 (24) (2020)
Chenyin Wang, Alexandra Hamacher, Patrick Petzsch, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann, Wolfgang A Schulz, Matthias Ulrich Kassack
Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1. Cancers 12 (2) (2020)
Marika Mokou, Vasiliki Lygirou, Ioanna Angelioudaki, Nikolaos Paschalidis, Rafael Stroggilos, Maria Frantzi, Agnieszka Latosinska, Aristotelis Bamias, Michèle Janine Hoffmann, Harald Mischak, Antonia Vlahou
A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures. Cancers 12 (12) (2020)
Alexander Lang, Patcharawalai Whongsiri, Merve Yilmaz, Tobias Lautwein, Patrick Petzsch, Annemarie Greife, Cagatay Gunes, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann, Wolfgang A Schulz
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. Cancers 12 (4) (2020)
Alessandro Nini, Michèle Janine Hoffmann, Rita Lampignano, Robert Große Siemer, Guus van Dalum, Tibor Szarvas, Cristina Lopez Cotarelo, Wolfgang Arthur Schulz, Dieter Niederacher, Hans Neubauer, Nikolas Hendrik Stoecklein, Guenter Niegisch
Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. Cytometry. Part B, Clinical cytometry 98 (4) (2020)
Lars Erichsen, Hans-Helge Seifert, Wolfgang A Schulz, Michèle Janine Hoffmann, Günter Niegisch, Marcos Jesus Araúzo-Bravo, Marcelo L Bendhack, Cedric Poyet, Thomas Hermanns, Agnes Beermann, Mohamed Hassan, Lisa Theis, Wardah Mahmood, Simeon Santourlidis
Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1. Scientific reports 10 (1) (2020)
Madeleine Sassenberg, Johanna Droop, Wolfgang A Schulz, Dimo Dietrich, Sophia Marie Loick, Constanze Wiek, Kathrin Scheckenbach, Nadine Therese Gaisa, Michèle Janine Hoffmann
Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma. BMC cancer 19 (1) (2019)
Ananda Ayyappan Jaguva Vasudevan, Michèle Janine Hoffmann, Michael L C Beck, Gereon Poschmann, Patrick Petzsch, Constanze Wiek, Kai Stühler, Karl Köhrer, Wolfgang A Schulz, Guenter Niegisch
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. International journal of molecular sciences 20 (9) (2019)
Margaretha A Skowron, Patrick Petzsch, Karin Hardt, Nicholas Wagner, Manfred Beier, Stefanie Thom, Matthias Drechsler, Harald Rieder, Karl Köhrer, Guenter Niegisch, Michèle Janine Hoffmann, Wolfgang A Schulz
Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. Scientific reports 9 (1) (2019)
Alexander Lang, Merve Yilmaz, Christiane Hader, Sammy Murday, Xenia Kunz, Nicholas Wagner, Constanze Wiek, Patrick Petzsch, Karl Köhrer, Julian Koch, Michèle Janine Hoffmann, Annemarie Greife, Wolfgang A Schulz
Contingencies of UTX/KDM6A Action in Urothelial Carcinoma. Cancers 11 (4) (2019)
Aline Kaletsch, Maria Pinkerneil, Michèle Janine Hoffmann, Ananda Ayyappan Jaguva Vasudevan, Chenyin Wang, Finn K Hansen, Constanze Wiek, Helmut Hanenberg, Christoph G W Gertzen, Holger Gohlke, Matthias Ulrich Kassack, Thomas Kurz, Wolfgang A Schulz, Guenter Niegisch
Effects of novel HDAC inhibitors on urothelial carcinoma cells. Clinical epigenetics 10 (1) (2018)